Ventracor Limited

Yesterday Australian shares closed 1% higher as most sectors surged. The benchmark S&P/ASX200 index rose 33.9 points, at 3480.2 while the All Ordinaries index was up 0.9%, or 30.60 points, at 3416.8. The local mining and energy sectors could be buoyed by the rising gold and oil prices today despite the negative lead from the US.

Ventracor Limited (ASX:VCR)(PINK:VTCRY) is responding to an article that appeared in today's "The Australian" newspaper, which in the Company's view makes incorrect and misleading allegations regarding the Company and its product the VentrAssist(R) Left Ventricular Assist Device (LVAD).

Ventracor Limited (ASX:VCR)(US:VTCRY) today announced that there have now been more than 250 patient implants of the VentrAssist(R) Left Ventricular Assist Device (LVAD).

Ventracor Limited (ASX:VCR)(US:VTCRY) today released the clinical results of the US Feasibility Trial of the VentrAssist(R) Left Ventricular Assist Device (LVAD). The results were presented on Saturday 12 April at the annual meeting of the International Society of Heart and Lung Transplantation (ISHLT) in Boston by Dr. Andrew Boyle, Assistant Professor of Medicine at the University of Minnesota Medical School, in Minneapolis MN.

Ventracor Limited (ASX: VCR)(PNK: VTCRY) CEO, Peter Crosby Letter to Shareholders

Ventracor Limited (ASX: VCR)(PNK: VTCRY) announced today changes to the Board of Directors. John Massey has retired as a Director and Chairman of the Board. John Ward has been elected Chairman of the Board of Directors, and William Curran takes on the role of Chairman of the Audit, Risk and Compliance Committee.

Ventracor Limited (ASX: VCR)(ADR: VTCRY) announced today that the US Food and Drug Administration (FDA) has granted unconditional approval for the US Destination Therapy Trial of the VentrAssist Left Ventricular Assist Device (LVAD).

Ventracor (ASX: VCR) announced today the appointment of Professor Mariell Jessup as Cardiology Principal Investigator of the US Destination Therapy Trial of the VentrAssist Left Ventricular Assist Device (LVAD).

Ventracor (ASX: VCR) has implanted the 200th patient with its VentrAssist(tm) Left Ventricular Assist Device (LVAD)

Ventracor (ASX: VCR) today announced CE Marking approval for the next version of the VentrAssist(tm) left ventricular assist device (LVAD) which allows it to be marketed and sold in Europe.